Klişe bir laf ama adamlar uzaya araç gönderirken, İslam dünyasında hâlâ dünya düz mü değil mi diye tartışılması gerçekten trajik. Bu tartışma birçok müslümana bile saçma gelecektir eminim. Ancak konu din olunca ve her şeyin ölçütü kutsal kitaplar olarak görüldüğünde, gerçeklerin orada yazanlara uydurulması bilindik bir durum haline gelmekte. İşte bu sebeple, 1975 yılında Suudi Arabistan'ın en önemli din otoritesi kabul edilen Şeyh Abdul Aziz Bin Baz tarafından Dünya'nın düz olduğu fetvası verilmiş ve buna inanmayanların dinsiz kabul edilerek, cezelandırılması gerektiği bildirilmiştir. Bugün, ülkemizde, hadisleri baz alarak Adem'in dinozorlarla aynı dönemde yaşadığını ve 30 m. uzunlukta olduğunu söyleyen biyoloji profesörlerimiz varken, dünyanın düz olduğunu söyleyen uzmanlar hiçbir müslümanı da şaşırtmamalı. ("Kuran'da Dünya'nın düz olarak geçtiğini söyleyenlere itirazınız var da, evrim yalandır diyenlere niye yok?" diye bir soru yönlendirilebilir kendilerine.)
Şüphesiz buna inananlar sadece müslümanlar değil. 1956 yılında Britanya'da, Flat Earth Society (Düz Dünya Cemiyeti) adıyla, Dünya'nın düz olduğunu savunan ve bugün hala aktif olan bir organizasyon bile kuruldu. Bilim karşıtlığı hiçbir zaman popülaritesini yitirmiyor.
Konuyla ilgili olarak aşağıdaki kaynaklara bakmanızı da tavsiye ederim:
http://www.bilimfelsefedin.org/?p=377
http://suphecimelek.wordpress.com/2010/05/21/gunesin-battigi-yer/
http://www.mucizeyalanlari.com/gunesin-gidis-istikameti/
http://wikiislam.net/wiki/Flat_Earth_and_the_Qur%27an (İngilizce)
http://www.loc.gov/exhibits/world/images/s104.jpg (Zekeriya bin Mahmut el Kazvini'nin 16. yy'da Arapça'dan Türkçe'ye çevrilmiş astronomi kitabı Acaibul Mahlukat'tan alınan bu tasvirde, Dünya bir büyükbaş hayvanın üzerinde duran düz bir disk olarak tasvir ediliyor.)
Society for Science & the Public (Society) today announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is the new title sponsor of the Science Talent Search. Selected through a competitive process that garnered interest from the nation’s leading companies and philanthropists, Regeneron will become only the third sponsor in 75 years of the nation’s oldest and most prestigious high school science competition.
The new sponsorship will be celebrated at a special event today at the American Museum of Natural History, which is known for its extensive science education program. The event will be hosted by astrophysicist Neil deGrasse Tyson, Ph.D., Frederick P. Rose director of the Hayden Planetarium at the American Museum of Natural History, and can be viewed via webcast at 9:00 a.m. EDT at http://edge.media-server.com/m/go/sciencetalentsearch.
Regeneron is committing $100 million to support the Science Talent Search and other Society programs through 2026 and will assume title sponsorship of the competition effectively immediately. As part of its commitment, Regeneron is nearly doubling the overall award distribution to $3.1 million annually, increasing the top award to $250,000, and doubling the awards for the top 300 young scientists and their schools to $2,000 each. During its history, the Science Talent Search has provided more than $25 million in awards to over 8,500 students and schools.
To view the multimedia release go to:
http://www.multivu.com/players/English/7846351-regeneron-science-talent-search/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
The Kokuryukai Black Dragon Society, IFAA International Fighting Arts Association has recognized Laoshi Douwe Geluk in 2019. Douwe Geluk is a martial arts master from Apeldoorn city in the Netherlands and founder of Tai Chi Apeldoorn Bron van Geluk Fu Yuan
A new survey from the Gout & Uric Acid Education Society (GUAES) finds many Americans with gout may be placing too much emphasis on diet when it comes to managing the disease and controlling painful flares. Of all the steps taken to manage gout, respondents cited changing their diet by eliminating or reducing consumption of certain foods as their top step taken (50 percent)—even ahead of taking medications to lower their uric acid levels (40 percent) and maintaining an overall healthy fitness level (33 percent). Furthermore, nearly one in three with gout incorrectly believes that the disease can be completely avoided by eliminating certain foods; and more than one in four said they would not take medications if they were making dietary changes.
“Physicians all too often see patients who believe they can successfully manage their gout with diet alone,” said N. Lawrence Edwards, M.D., a rheumatologist and GUAES chairman. “But even with extremely rigid diet restrictions, most gout patients will only be able to lower their uric acid levels slightly—not nearly enough to achieve a healthy level to control flares and reduce risk for long-term damage.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7835451-guaes-diet-survey/
As the country celebrates the 45th anniversary of Earth Day, Dallas-based nonprofit Earth Day Texas gears up for its fifth annual event. Founded in 2011, the organization expects more than 75,000 attendees during the three-day event.
Earth Day Texas takes place April 24, 25 and 26 at historic Fair Park in Dallas.
Confirmed speakers include Karenna Gore, author and daughter of Al Gore; Bill White, former mayor of Houston; David Yarnold, president of the Audubon Society; Dan Patrick, Lt. Governor of Texas; B.A. Norrgard, Tiny House advocate; Laura Turner Seydel, chairperson of the Captain Planet Foundation; and Louie Psihoyos, Oscar®-winning director of The Cove.
Seven-time Grammy Award winner Paul Winter will perform on Saturday, April 25, at 4:30 p.m. Grammy nominated artist Michael Martin Murphey will perform on Sunday, April 26, at 4:45 p.m.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7500951-earth-day-texas/
Whirlpool Corporation is celebrating the conclusion of its first-ever Global Habitat Build Project -- a project which engaged more than 200 Whirlpool Corporation employee volunteers in 14 Habitat for Humanity home build projects in eight countries. The project was coordinated to recognize the many contributions of the company’s former CEO, Jeff Fettig, who stepped down as CEO on October 31 of this year, and to celebrate the 17-year partnership between Habitat for Humanity International and Whirlpool Corporation.
“What better way to recognize the standard of giving back set by our Chairman and former CEO, Jeff Fettig, than to collectively build homes around the world in his honor,” said Jeff Noel, the corporate vice president of communications & public affairs for Whirlpool Corporation. “At the same time, we’re celebrating our long-standing relationship with Habitat for Humanity. Jonathan Reckford, CEO of Habitat for Humanity International, gave his time to hammer nails alongside our employees, honoring our collaborative work building homes and positively impacting society for nearly two decades.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8219351-whirlpool-celebrates-global-habitat-build-project/
The 6th forum has become a record-breaking one by every measure by gathering 18,200 participants from 98 countries. During three thematic day-long sessions on business, government and society, presentations of more than 650 speakers took place.
Within the framework of the forum business program and in the press center 42 agreements were signed, including 24 partnership agreements with the Skolkovo Foundation. Notably some agreements deal with billion ruble infrastructural projects, such as, e.g. deploying the 5G network in Skolkovo, while other ones suggest direct investments of hundred million rubles, such as the agreement between VEB and IIDF amounting to 200 million dollars or the agreement between IBS company and “Skolkovo Venture – IT I” amounting to 100 million rubles.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8210651-open-innovations-2017-record-breaking/
The National Inventors Hall of Fame®, in partnership with the United States Patent and Trademark Office (USPTO), will host the Greatest Celebration of American Innovation on May 3-4 in our Nation’s Capital. Events will recognize and celebrate 15 pioneers who have significantly contributed to society through their scientific breakthroughs and patented innovations, culminating in a formal Induction Ceremony on May 4.
This year’s class of Inductees includes innovators such as Iver Anderson (Lead-Free Solder), Marshall Jones (Industrial Lasers), Frances Ligler (Portable Optical Biosensors), and Howard Head (Laminate Ski; Oversized Tennis Racket), just to name a few. To view the full list of 2017 Inductees, visit: http://prn.to/2lgdW84.
To view the multimedia release go to:
https://www.multivu.com/players/English/8040951-national-inventors-hall-of-fame-2017/
Let’s Win, an initiative supported by the Lustgarten Foundation, launched the Let’s Win! Pancreatic Cancer Survivors video series Friday, January 19, 2018, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The new online video series, featuring long-term pancreatic cancer survivors of all ages and diverse backgrounds, has been created to show pancreatic cancer patients and their families that people do survive this disease. The survivors have responded exceptionally well to pancreatic cancer therapy that incorporates clinical trials and treatments that go beyond traditional protocols.
When patients are first diagnosed with pancreatic cancer, they often turn to the internet, only to find devastating and frightening statistics about the disease. “Our goal is to provide hope and inspiration to patients and their families,” says Cindy Gavin, founding executive director of Let’s Win. “We are so grateful for the incredible vision of one special patient and the generosity of The Flora Family Foundation for their support of this incredible initiative.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213752-lets-win-pancreatic-cancer-survivor-video-series/
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
